Personalised cancer management: Closer, but not here yet

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 1951-1955

  Piccart, Martine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; PLACEBO; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB; VASCULOTROPIN ANTIBODY;

ADVANCED CANCER; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; EDITORIAL; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT PLANNING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84881252783     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt260     Document Type: Editorial

References (34)

1. http://ec.europa.eu/research/horizon2020/pdf/proposals/proposal_for_a_ regulation_of_the_european_parliament_and_of_the_council_establishing_ horizon_2020_-_the_framework_programme_for_research_and_innovation_ (2014-2020).pdf#view=fit&pagemode=none (16 May 2013, date last accessed).
2. Criscitiello C, Curigliano G. HER2 signaling pathway and trastuzumab cardiotoxicity. Future Oncol 2013; 9: 179-181.
3. Eiermann W, Rezai M, Kümmel S et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol 2013; 24: 618-624.
4. Jelovac D, Emens LA. HER2 directed therapy for metastatic breast cancer. Oncology (Williston Park) 2013; 27: 166-175.
5. Weigelt B, Reis-Filho JS, Swanton C. Genomic analysis to select patients for adjuvant chemotherapy: trials and tribulations. Ann Oncol 2012; 23(Suppl 10): x211-x218.
6. Di Leo A, Desmedt C, Bartlett JM et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 2011; 12: 1134-1142.
7. Gianni L, Eiermann W, Semiglazov V et al. Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT1H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer. J Clin Oncol 2013; 31(15S): 7s.
8. Criscitiello C, Azim HA, Agbor-tarh D et al. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER-positive breast cancer: results from the NeoALLTO phase III trial. Ann Oncol 2013; 24: 1980-1985.
9. Ollila DW, Berry DA, Cirrincione B et al. Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance). J Clin Oncol 2013; 31(15S): 7s.
10. Andersson M, Lidbrink E, Bjerre K et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor-2 positive breast cancer: the HERNATA study. J Clin Oncol 2011; 29: 264-271.
11. Swain SM, Kim SB, Cortes J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2013; 14: 461-471.
12. Gelmon KE, Boyle F, Kaufman B et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy with lapatinib or trastuzumab as firstline therapy for women with HER2+ metastatic breast cancer: interim analysis of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 2012; 30(15)_suppl (May 20 Supplement): LBA671.
13. Blackwell KL, Burstein HJ, Storniolo AM et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor-2 positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012; 30: 2585-2592.
14. Bose R, Kavuri SM, Searleman AC et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013; 3: 1-14.
15. Pivot X, Semiglazov V, Zurawski B et al. CEREBEL (EGF111438): An open label randomized phase III study comparing the incidence of CNS metastases in patients with HER2+ metastatic breast cancer treated with lapatinib plus capecitabine versus trastuzumab plus capecitabine. Ann Oncol 2012; 23(suppl 9): LBA11.
16. Bachelot T, Romieu G, Campone M et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013; 14(1): 64-71. Epub 2012 Nov 2.
17. Perez EA, Suman VJ, Davidson NE et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011; 29: 4491-4497.
18. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-1283.
19. Schmoll HJ, van Cutsem E, Stein A et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to decision making. Ann Oncol 2012; 23: 2479-2516.
20. Prenen H, Vecchione L, Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Target Oncol 2013; 8(2): 83-96.
21. Karapetis K, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
22. Tveit KM, Guren T, Glimelius B et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30: 1755-1762.
23. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatinbased first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114.
24. Diaz LR, Williams RT, Wu J et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537-540.
25. Misale S, Yaeger R, Hobor S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-536.
26. Bardelli A, Corso S, Bertotti A et al. Amplification of the MET receptor to drive resistance to anti-EGFR therapies in colorectal cancer. J Clin Onc 2013; 31(15S): 657s.
27. Marshall JL. Vascular endothelial growth factor plus epidermal growth factor receptor dual targeted therapy in metastatic colorectal cancer: synergy or antagonism? J Clin Oncol 2009; 2009, doi: 10.1155/2009/937305.
28. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for nonsmall- cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
29. Lindeman NI, Cagle PT, Beasley MB et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013; 15(4): 1-39.
30. Arcila ME, Chaft JE, Nafa K et al. Prevalence, clinicopathologic associations and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012; 18: 4910-4918.
31. Gatalica Z, Gupta A, Ghazalpour C et al. HER2 in non-small cell lung carcinoma. Lung Cancer 2013; 80(Suppl. 1): S30.
32. Mazières J, Peters S, Lepage B et al. Lung cancer that harbors a HER2 mutation: Epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013; 31 (16): 1997-2003.
33. Thunniessen E, Kerr K, Herth FJ et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 2012; 76(1): 1-18.
34. Barlesi F, Blons H, Beau-Faller M et al. Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10000 non-small cell lung cancer (NSCLC) patients ( pts). J Clin Oncol 2013; 31(15S): 486s.